AGÕæÈ˹ٷ½

STOCK TITAN

Tenet Reports Strong First Quarter 2025 Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
  • Net income available to common shareholders in first quarter 2025 was $406 million, or $4.27 per diluted share
  • Adjusted diluted earnings per share1 increased 35.4% to $4.36 in first quarter 2025 compared to $3.22 in first quarter 2024
  • Consolidated Adjusted EBITDA1 in first quarter 2025 increased 13.6% to $1.163 billion compared to first quarter 2024; First quarter 2025 Adjusted EBITDA margin was 22.3%
  • First quarter 2025 Ambulatory Care Adjusted EBITDA of $456 million increased 15.7% over first quarter 2024
  • FY 2025 Adjusted EBITDA Outlook is expected to be in the range of $3.975 billion to $4.175 billion

DALLAS--(BUSINESS WIRE)-- Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended March 31, 2025.

"We had an excellent start to the year driven by strong same-store revenue growth and operational discipline, resulting in earnings and cash flows well ahead of our expectations," said Saum Sutaria, M.D., Chairman and Chief Executive Officer of Tenet. "We continue to expand access to high-quality specialty care as we effectively execute on our mission to deliver quality, compassionate care in the communities we serve."

Tenet’s results for first quarter 2025 versus first quarter 2024 are as follows:

Ìý

Three Months Ended
March 31,

($ in millions, except per share results)

2025

2024

Net operating revenues

$5,223

$5,368

Net income available to Tenet common shareholders

$406

$2,151

Net income available to Tenet common shareholders per diluted share

$4.27

$21.38

Adjusted EBITDA1

$1,163

$1,024

Adjusted diluted earnings per share1

$4.36

$3.22

  • Net income available to the Company’s common shareholders in first quarter 2025 was $406 million, or $4.27 per diluted share, versus $2.151 billion, or $21.38 per diluted share, in first quarter 2024. First quarter 2024 results included a pre-tax gain of $2.5 billion ($1.856 billion after-tax, or $18.45 per diluted share) primarily associated with the divestiture of three hospitals in South Carolina and six hospitals in California.
  • Adjusted EBITDA1 in first quarter 2025 was $1.163 billion compared to $1.024 billion in first quarter 2024, reflecting strong growth in same-hospital admissions and ambulatory net revenue per case, favorable payer mix, and disciplined expense management, partially offset by the impact of hospital divestitures.
  • In the first quarter of 2025, the Company recognized a $40 million favorable pre-tax impact associated with additional Medicaid supplemental revenues related to prior years. First quarter 2024 results included a $44 million favorable pre-tax impact for additional Medicaid supplemental revenues related to the last three months of 2023.

Balance Sheet and Cash Flows

  • Cash flows provided by operating activities for the three months ended March 31, 2025 were $815 million versus $586 million for the three months ended March 31, 2024.
  • The Company produced free cash flow1 of $642 million for the three months ended March 31, 2025 versus $346 million for the three months ended March 31, 2024.
  • In the three months ended March 31, 2025, the Company repurchased 2,629,195 shares of common stock for $348 million.
  • The Company’s ratio of net debt to Adjusted EBITDA1 was 2.46x at March 31, 2025 compared to 2.54x at December 31, 2024.

Ambulatory Care (Ambulatory) Segment

Tenet’s Ambulatory business segment is comprised of the operations of United Surgical Partners International (USPI). As of March 31, 2025, USPI had interests in 520 ambulatory surgery centers (380 consolidated) and 25 surgical hospitals (seven consolidated) in 37 states.

Ìý

Three Months Ended
March 31,

Ambulatory segment results ($ in millions)

2025

2024

Revenues

Ìý

Ìý

Net operating revenues

$1,194

$995

Same-facility system-wide net patient service revenues2

$1,945

$1,821

Changes versus the Prior-Year Period

Ìý

Ìý

Same-facility system-wide net patient service revenues

6.8 %

6.4 %

Same-facility system-wide net patient service revenue per case

9.1 %

6.8 %

Same-facility system-wide surgical cases2

(2.1) %

(0.4) %

Same-facility system-wide surgical cases on same-business day basis2

(0.6) %

(0.4) %

Adjusted EBITDA, Margins and NCI

Ìý

Ìý

Adjusted EBITDA

$456

$394

Adjusted EBITDA margin

38.2%

39.6%

Adjusted EBITDA less NCI

$279

$241

  • First quarter 2025 net operating revenues increased 20.0% compared to first quarter 2024 driven by strong net revenue per case growth, acquisitions of facilities, and increased service lines.
  • Surgical business same-facility system-wide net patient service revenues increased 6.8% in first quarter 2025 compared to first quarter 2024, with cases down 2.1% and net revenue per case up 9.1%. Net revenue per case growth was driven by favorable case mix, increases in higher acuity volumes over the prior year, as well as favorable payer mix.
  • First quarter 2025 Adjusted EBITDA increased 15.7% compared to first quarter 2024, due to strong net revenue per case growth, disciplined expense management, and contributions from acquisitions.

Hospital Operations and Services (Hospital) Segment

Tenet’s Hospital business segment is primarily comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro-hospitals and physician practices. It also provides comprehensive end-to-end and focused point services, including hospital and physician revenue cycle management, patient communications and engagement support and value-based care solutions.

Ìý

Three Months Ended
March 31,

Hospital segment results ($ in millions)

2025

2024

Revenues

Ìý

Ìý

Net operating revenues

$4,029

$4,373

Same-hospital net patient service revenues3

$3,460

$3,271

Same-Hospital Volume Changes versus the Prior-Year Period

Ìý

Ìý

Admissions

4.4%

4.2%

Adjusted admissions4

2.9%

1.8%

Outpatient visits (including outpatient ER visits)

0.7%

(0.8)%

Emergency Room visits (inpatient and outpatient)

1.4%

3.9%

Hospital surgeries

(1.4)%

(2.0)%

Adjusted EBITDA

Ìý

Ìý

Adjusted EBITDA

$707

$630

Adjusted EBITDA margin

17.5%

14.4%

  • First quarter 2025 net operating revenues declined 7.9% from first quarter 2024 primarily due to the impact of hospital divestitures in 2024, partially offset by strong same hospital admissions growth, and favorable payer mix.
  • Same-hospital net patient service revenue per adjusted admission increased 2.8% year-over-year for first quarter 2025 primarily due to favorable payer mix, and our focus on growing higher acuity services.
  • Adjusted EBITDA in first quarter 2025 was $707 million compared to $630 million in first quarter 2024, reflecting strong same-hospital admissions growth and revenue per adjusted admission, favorable payer mix, and disciplined expense management, partially offset by the impact of hospital divestitures.
  • In the first quarter of 2025, the Company recognized a $40 million favorable pre-tax impact associated with additional Medicaid supplemental revenues related to prior years. First quarter 2024 results included a $44 million favorable pre-tax impact for additional Medicaid supplemental revenues related to the last three months of 2023.

2025 Outlook1

Tenet’s Outlook for full year 2025 (consolidated and by segment) follows.

CONSOLIDATED ($ in millions, except per share amounts)

FY 2025 Outlook

Net operating revenues

$20,600 to $21,000

Net income available to Tenet common stockholders

$1,057 to $1,202

Adjusted EBITDA

$3,975 to $4,175

Adjusted EBITDA margin

19.3% to 19.9%

Diluted income per common share

$11.37 to $12.92

Adjusted net income

$1,115 to $1,220

Adjusted diluted earnings per share

$11.99 to $13.12

Equity in earnings of unconsolidated affiliates

$265 to $275

Depreciation and amortization

$805 to $835

Interest expense

$795 to $805

Income tax expense5

$425 to $470

Net income available to NCI

$910 to $960

Weighted average diluted common shares

~93 million

Net cash provided by operating activities

$2,500 to $2,850

Adjusted net cash provided by operating activities

$2,600 to $2,900

Capital expenditures

$700 to $800

Free cash flow

$1,800 to $2,050

Adjusted free cash flow

$1,900 to $2,100

NCI cash distributions

$750 to $800

Ambulatory Segment ($ in millions)

FY 2025 Outlook

Net operating revenues

$4,850 to $5,000

Adjusted EBITDA

$1,915 to $1,985

NCI

$760 to $790

Adjusted EBITDA less NCI

$1,155 to $1,195

Changes versus prior year6:

Ìý

Same-facility system-wide revenue

Up 3.0% to 6.0%

Hospital Segment ($ in millions)

FY 2025 Outlook

Net operating revenues

$15,750 to $16,000

Adjusted EBITDA

$2,060 to $2,190

NCI

$150 to $170

Changes versus prior year6:

Ìý

Inpatient admissions

Up 2.0% to 3.0%

Adjusted admissions

Up 2.0% to 3.0%

Management’s Webcast Discussion of Results

Tenet management will discuss the Company’s first quarter 2025 results in a webcast scheduled for 10:00 a.m. Eastern Time (9:00 a.m. Central Time) on April 29, 2025. Investors can access the webcast through the Company’s website at .

The slide presentation associated with the webcast referenced above, a copy of this earnings press release, and a related supplemental financial disclosures document will be available on the Company’s Investor Relations website on April 29, 2025.

Cautionary Statement

This release contains “forward-looking statements� - that is, statements that relate to future, not past, events. In this context, forward-looking statements often address the Company’s expected future business and financial performance and financial condition, and often contain words such as “expect,� “anticipate,� “assume,� “believe,� “budget,� “estimate,� “forecast,� “intend,� “plan,� “predict,� “project,� “seek,� “see,� “target,� or “will.� Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Particular uncertainties that could cause the Company’s actual results to be materially different than those expressed in the Company’s forward-looking statements include, but are not limited to the factors disclosed under “Forward-Looking Statements� and “Risk Factors� in our Form 10-K for the year ended December 31, 2024 and other filings with the Securities and Exchange Commission.

Footnotes

  1. Tables and discussions throughout this earnings release include certain financial measures, including those related to our full year 2025 Outlook, that are not in accordance with accounting principles generally accepted in the United States of America (GAAP). Reconciliations of GAAP measures to the Adjusted (non-GAAP) measures used are detailed in Tables #1-6 included at the end of this earnings release. Management’s reasoning for the use of these non-GAAP measures and descriptions of the various non-GAAP measures are included in the Non-GAAP Financial Measures section of this earnings release.
  2. Same-facility system-wide revenues and statistical information include the results of the facilities in which the Ambulatory segment has an investment that are not consolidated by Tenet. To help analyze the segment’s results of operations, management uses system-wide measures, which include revenues and cases of both consolidated and unconsolidated facilities.
  3. For 2025, same-hospital revenues and statistical data include those for hospitals and hospital-affiliated outpatient centers operated by the Company’s Hospital segment continuously from January 1, 2024 through March 31, 2025. Amounts associated with physician practices are excluded.
  4. Adjusted admissions represent actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues, then dividing that result by gross inpatient revenues.
  5. Income tax expense is calculated by multiplying 24% (the federal corporate tax rate of 21% plus an estimate of state taxes) by the sum of: pretax income less GAAP facility level NCI expense plus permanent differences, and non-deductible interest expense.
  6. Change versus prior year is presented on a same-facility system-wide basis for USPI Ambulatory surgical cases and on a same-hospital basis for hospital statistics.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit .

Non-GAAP Financial Measures

The Company believes the non-GAAP measures described below are useful to investors and analysts because they present additional information on the Company’s financial performance. Investors, analysts, Company management and the Company’s Board of Directors utilize these non-GAAP measures, in addition to GAAP measures, to track the Company’s financial and operating performance and compare the Company’s performance to its peer companies, which use similar non-GAAP financial measures in their presentations and earnings releases. The Human Resources Committee of the Company’s Board of Directors also uses certain of these measures to evaluate management’s performance for the purpose of determining incentive compensation. Additional information regarding the purpose and utility of specific non-GAAP measures used in this release is set forth below.

  • Adjusted EBITDA is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) the cumulative effect of changes in accounting principles, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, net of tax, (4) income tax benefit (expense), (5) gain (loss) from early extinguishment of debt, (6) other non-operating income (expense), net, (7) interest expense, (8) litigation and investigation benefit (costs), net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-related costs, (11) depreciation and amortization and (12) income (loss) from divested and closed businesses (i.e., health plan businesses). Litigation and investigation costs excluded do not include ordinary course of business malpractice and other litigation and related expenses.
  • Adjusted diluted earnings (loss) per share is defined by the Company as Adjusted net income available (loss attributable) to Tenet common shareholders, divided by the weighted average diluted shares outstanding in the reporting period.
  • Adjusted net income available (loss attributable) to Tenet common shareholders is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) income (loss) from discontinued operations, net of tax, (2) gain (loss) from early extinguishment of debt, (3) litigation and investigation benefit (costs), net of insurance recoveries, (4) net gains (losses) on sales, consolidation and deconsolidation of facilities, (5) impairment and restructuring charges and acquisition-related costs, (6) income (loss) from divested and closed businesses (i.e., health plan businesses) and (7) the associated impact of these items on taxes and noncontrolling interests. Litigation and investigation costs excluded do not include ordinary course of business malpractice and other litigation and related expenses.
  • Free Cash Flow is defined by the Company as (1) net cash provided by (used in) operating activities, less (2) purchases of property and equipment.
  • Adjusted Free Cash Flow is defined by the Company as (1) Adjusted net cash provided by (used in) operating activities, less (2) purchases of property and equipment.
  • Adjusted net cash provided by (used in) operating activities is defined by the Company as cash provided by (used in) operating activities prior to (1) payments for restructuring charges, acquisition-related costs and litigation costs and settlements, and (2) net cash provided by (used in) operating activities from discontinued operations.

The Company believes that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to other GAAP and non-GAAP measures, as factors in determining the estimated fair value of shares of the Company’s common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company does not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance.

The Company uses, and believes investors use, Free Cash Flow and Adjusted Free Cash Flow as supplemental non-GAAP measures to analyze cash flows generated from the Company’s operations. The Company believes these measures are useful to investors in evaluating its ability to fund distributions paid to noncontrolling interests or for acquisitions, purchasing equity interests in joint ventures or repaying debt.

These non-GAAP measures may not be comparable to similarly titled measures reported by other companies. Because these measures exclude many items that are included in the Company’s financial statements, they do not provide a complete measure of the Company’s operating performance. For example, the Company’s definitions of Free Cash Flow and Adjusted Free Cash Flow do not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows from Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, or (ii) distributions paid to noncontrolling interests. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company’s financial performance.

See corresponding reconciliations of the non-GAAP financial measures referred to above to the most comparable GAAP financial measures in Tables #1 - 6 below.

Tenet Healthcare Corporation

Financial Statements and Reconciliations

First Quarter Earnings Release

Ìý

Table of Contents

Description

Page

Consolidated Statements of Operations

12

Consolidated Balance Sheets

13

Consolidated Statements of Cash Flows

14

Segment Reporting

15

Table #1 � Reconciliations of Net Income to Adjusted Net Income

16

Table #2 � Reconciliations of Net Income to Adjusted EBITDA

17

Table #3 � Reconciliations of Net Cash Provided by Operating Activities to Free Cash Flow and Adjusted Free Cash Flow

18

Table #4 � Reconciliations of Outlook Net Income to Outlook Adjusted Net Income

19

Table #5 � Reconciliations of Outlook Net Income to Outlook Adjusted EBITDA

20

Table #6 � Reconciliations of Outlook Net Cash Provided by Operating Activities to Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow

21

TENET HEALTHCARE CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Ìý

(Dollars in millions, except per share amounts)

Ìý

Three Months Ended March 31,

Ìý

Ìý

2025

Ìý

Ìý

%

Ìý

Ìý

2024

Ìý

Ìý

%

Ìý

Change

Net operating revenues

Ìý

$

5,223

Ìý

Ìý

100.0

%

Ìý

$

5,368

Ìý

Ìý

100.0

%

Ìý

(2.7

)%

Equity in earnings of unconsolidated affiliates

Ìý

Ìý

56

Ìý

Ìý

1.1

%

Ìý

Ìý

59

Ìý

Ìý

1.1

%

Ìý

(5.1

)%

Operating expenses:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Salaries, wages and benefits

Ìý

Ìý

2,119

Ìý

Ìý

40.6

%

Ìý

Ìý

2,321

Ìý

Ìý

43.2

%

Ìý

(8.7

)%

Supplies

Ìý

Ìý

907

Ìý

Ìý

17.4

%

Ìý

Ìý

928

Ìý

Ìý

17.3

%

Ìý

(2.3

)%

Other operating expenses, net

Ìý

Ìý

1,090

Ìý

Ìý

20.9

%

Ìý

Ìý

1,154

Ìý

Ìý

21.5

%

Ìý

(5.5

)%

Depreciation and amortization

Ìý

Ìý

206

Ìý

Ìý

3.9

%

Ìý

Ìý

208

Ìý

Ìý

3.9

%

Ìý

Ìý

Impairment and restructuring charges, and acquisition-related costs

Ìý

Ìý

19

Ìý

Ìý

0.3

%

Ìý

Ìý

27

Ìý

Ìý

0.5

%

Ìý

Ìý

Litigation and investigation costs

Ìý

Ìý

17

Ìý

Ìý

0.3

%

Ìý

Ìý

4

Ìý

Ìý

0.1

%

Ìý

Ìý

Net gains on sales, consolidation and deconsolidation of facilities

Ìý

Ìý

(22

)

Ìý

(0.4

)%

Ìý

Ìý

(2,500

)

Ìý

(46.6

)%

Ìý

Ìý

Operating income

Ìý

Ìý

943

Ìý

Ìý

18.1

%

Ìý

Ìý

3,285

Ìý

Ìý

61.2

%

Ìý

Ìý

Interest expense

Ìý

Ìý

(204

)

Ìý

Ìý

Ìý

Ìý

(218

)

Ìý

Ìý

Ìý

Ìý

Other non-operating income, net

Ìý

Ìý

26

Ìý

Ìý

Ìý

Ìý

Ìý

25

Ìý

Ìý

Ìý

Ìý

Ìý

Loss from early extinguishment of debt

Ìý

Ìý

�

Ìý

Ìý

Ìý

Ìý

Ìý

(8

)

Ìý

Ìý

Ìý

Ìý

Income before income taxes

Ìý

Ìý

765

Ìý

Ìý

Ìý

Ìý

Ìý

3,084

Ìý

Ìý

Ìý

Ìý

Ìý

Income tax expense

Ìý

Ìý

(143

)

Ìý

Ìý

Ìý

Ìý

(750

)

Ìý

Ìý

Ìý

Ìý

Net income

Ìý

Ìý

622

Ìý

Ìý

Ìý

Ìý

Ìý

2,334

Ìý

Ìý

Ìý

Ìý

Ìý

Less: Net income available to noncontrolling interests

Ìý

Ìý

216

Ìý

Ìý

Ìý

Ìý

Ìý

183

Ìý

Ìý

Ìý

Ìý

Ìý

Net income available to Tenet Healthcare Corporation common shareholders

Ìý

$

406

Ìý

Ìý

Ìý

Ìý

$

2,151

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Earnings available to Tenet Healthcare Corporation common shareholders:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Basic

Ìý

$

4.31

Ìý

Ìý

Ìý

Ìý

$

21.60

Ìý

Ìý

Ìý

Ìý

Ìý

Diluted

Ìý

$

4.27

Ìý

Ìý

Ìý

Ìý

$

21.38

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Weighted average shares and dilutive securities outstanding (in thousands):

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Basic

Ìý

Ìý

94,242

Ìý

Ìý

Ìý

Ìý

Ìý

99,581

Ìý

Ìý

Ìý

Ìý

Ìý

Diluted

Ìý

Ìý

95,019

Ìý

Ìý

Ìý

Ìý

Ìý

100,598

Ìý

Ìý

Ìý

Ìý

Ìý

TENET HEALTHCARE CORPORATION

CONSOLIDATED BALANCE SHEETS

(Unaudited)

Ìý

(Dollars in millions)

Ìý

March 31,

Ìý

December 31,

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

ASSETS

Ìý

Ìý

Ìý

Ìý

Current assets:

Ìý

Ìý

Ìý

Ìý

Cash and cash equivalents

Ìý

$

2,999

Ìý

Ìý

$

3,019

Ìý

Accounts receivable

Ìý

Ìý

2,619

Ìý

Ìý

Ìý

2,536

Ìý

Inventories of supplies, at cost

Ìý

Ìý

344

Ìý

Ìý

Ìý

346

Ìý

Assets held for sale

Ìý

Ìý

21

Ìý

Ìý

Ìý

21

Ìý

Other current assets

Ìý

Ìý

1,930

Ìý

Ìý

Ìý

1,760

Ìý

Total current assets

Ìý

Ìý

7,913

Ìý

Ìý

Ìý

7,682

Ìý

Investments and other assets

Ìý

Ìý

3,069

Ìý

Ìý

Ìý

3,037

Ìý

Deferred income taxes

Ìý

Ìý

78

Ìý

Ìý

Ìý

80

Ìý

Property and equipment, at cost, less accumulated depreciation and amortization

Ìý

Ìý

5,991

Ìý

Ìý

Ìý

6,049

Ìý

Goodwill

Ìý

Ìý

10,786

Ìý

Ìý

Ìý

10,691

Ìý

Other intangible assets, at cost, less accumulated amortization

Ìý

Ìý

1,400

Ìý

Ìý

Ìý

1,397

Ìý

Total assets

Ìý

$

29,237

Ìý

Ìý

$

28,936

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

LIABILITIES AND EQUITY

Ìý

Ìý

Ìý

Ìý

Current liabilities:

Ìý

Ìý

Ìý

Ìý

Current portion of long-term debt

Ìý

$

88

Ìý

Ìý

$

92

Ìý

Accounts payable

Ìý

Ìý

1,327

Ìý

Ìý

Ìý

1,294

Ìý

Accrued compensation and benefits

Ìý

Ìý

710

Ìý

Ìý

Ìý

899

Ìý

Professional and general liability reserves

Ìý

Ìý

268

Ìý

Ìý

Ìý

238

Ìý

Accrued interest payable

Ìý

Ìý

248

Ìý

Ìý

Ìý

149

Ìý

Liabilities held for sale

Ìý

Ìý

12

Ìý

Ìý

Ìý

13

Ìý

Income tax payable

Ìý

Ìý

149

Ìý

Ìý

Ìý

18

Ìý

Other current liabilities

Ìý

Ìý

1,649

Ìý

Ìý

Ìý

1,607

Ìý

Total current liabilities

Ìý

Ìý

4,451

Ìý

Ìý

Ìý

4,310

Ìý

Long-term debt, net of current portion

Ìý

Ìý

13,082

Ìý

Ìý

Ìý

13,081

Ìý

Professional and general liability reserves

Ìý

Ìý

877

Ìý

Ìý

Ìý

900

Ìý

Defined benefit plan obligations

Ìý

Ìý

297

Ìý

Ìý

Ìý

298

Ìý

Deferred income taxes

Ìý

Ìý

226

Ìý

Ìý

Ìý

227

Ìý

Other long-term liabilities

Ìý

Ìý

1,651

Ìý

Ìý

Ìý

1,573

Ìý

Total liabilities

Ìý

Ìý

20,584

Ìý

Ìý

Ìý

20,389

Ìý

Commitments and contingencies

Ìý

Ìý

Ìý

Ìý

Redeemable noncontrolling interests in equity of consolidated subsidiaries

Ìý

Ìý

2,776

Ìý

Ìý

Ìý

2,727

Ìý

Equity:

Ìý

Ìý

Ìý

Ìý

Shareholders� equity:

Ìý

Ìý

Ìý

Ìý

Common stock

Ìý

Ìý

8

Ìý

Ìý

Ìý

8

Ìý

Additional paid-in capital

Ìý

Ìý

4,826

Ìý

Ìý

Ìý

4,873

Ìý

Accumulated other comprehensive loss

Ìý

Ìý

(178

)

Ìý

Ìý

(180

)

Retained earnings

Ìý

Ìý

3,414

Ìý

Ìý

Ìý

3,008

Ìý

Common stock in treasury, at cost

Ìý

Ìý

(3,889

)

Ìý

Ìý

(3,538

)

Total shareholders� equity

Ìý

Ìý

4,181

Ìý

Ìý

Ìý

4,171

Ìý

Noncontrolling interests

Ìý

Ìý

1,696

Ìý

Ìý

Ìý

1,649

Ìý

Total equity

Ìý

Ìý

5,877

Ìý

Ìý

Ìý

5,820

Ìý

Total liabilities and equity

Ìý

$

29,237

Ìý

Ìý

$

28,936

Ìý

TENET HEALTHCARE CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Ìý

(Dollars in millions)

Ìý

Three Months Ended

Ìý

March 31,

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Net income

Ìý

$

622

Ìý

Ìý

$

2,334

Ìý

Adjustments to reconcile net income to net cash provided by operating activities:

Ìý

Ìý

Ìý

Ìý

Depreciation and amortization

Ìý

Ìý

206

Ìý

Ìý

Ìý

208

Ìý

Deferred income tax expense (benefit)

Ìý

Ìý

4

Ìý

Ìý

Ìý

(38

)

Stock-based compensation expense

Ìý

Ìý

21

Ìý

Ìý

Ìý

17

Ìý

Impairment and restructuring charges, and acquisition-related costs

Ìý

Ìý

19

Ìý

Ìý

Ìý

27

Ìý

Litigation and investigation costs

Ìý

Ìý

17

Ìý

Ìý

Ìý

4

Ìý

Net gains on sales, consolidation and deconsolidation of facilities

Ìý

Ìý

(22

)

Ìý

Ìý

(2,500

)

Loss from early extinguishment of debt

Ìý

Ìý

�

Ìý

Ìý

Ìý

8

Ìý

Equity in earnings of unconsolidated affiliates, net of distributions received

Ìý

Ìý

5

Ìý

Ìý

Ìý

3

Ìý

Amortization of debt discount and debt issuance costs

Ìý

Ìý

6

Ìý

Ìý

Ìý

8

Ìý

Other items, net

Ìý

Ìý

2

Ìý

Ìý

Ìý

(5

)

Changes in cash from operating assets and liabilities:

Ìý

Ìý

Ìý

Ìý

Accounts receivable

Ìý

Ìý

(69

)

Ìý

Ìý

(263

)

Inventories and other current assets

Ìý

Ìý

(108

)

Ìý

Ìý

(18

)

Income taxes

Ìý

Ìý

132

Ìý

Ìý

Ìý

783

Ìý

Accounts payable, accrued expenses and other current liabilities

Ìý

Ìý

24

Ìý

Ìý

Ìý

19

Ìý

Other long-term liabilities

Ìý

Ìý

(8

)

Ìý

Ìý

24

Ìý

Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements

Ìý

Ìý

(36

)

Ìý

Ìý

(25

)

Net cash provided by operating activities

Ìý

Ìý

815

Ìý

Ìý

Ìý

586

Ìý

Cash flows from investing activities:

Ìý

Ìý

Ìý

Ìý

Purchases of property and equipment

Ìý

Ìý

(173

)

Ìý

Ìý

(240

)

Purchases of businesses or joint venture interests, net of cash acquired

Ìý

Ìý

(27

)

Ìý

Ìý

(449

)

Proceeds from sales of facilities and other assets

Ìý

Ìý

11

Ìý

Ìý

Ìý

4,030

Ìý

Proceeds from sales of marketable securities and long-term investments

Ìý

Ìý

14

Ìý

Ìý

Ìý

7

Ìý

Purchases of marketable securities and long-term investments

Ìý

Ìý

(17

)

Ìý

Ìý

(10

)

Other items, net

Ìý

Ìý

5

Ìý

Ìý

Ìý

(10

)

Net cash provided by (used in) investing activities

Ìý

Ìý

(187

)

Ìý

Ìý

3,328

Ìý

Cash flows from financing activities:

Ìý

Ìý

Ìý

Ìý

Repayments of borrowings

Ìý

Ìý

(32

)

Ìý

Ìý

(2,141

)

Proceeds from borrowings

Ìý

Ìý

1

Ìý

Ìý

Ìý

2

Ìý

Repurchases of common stock

Ìý

Ìý

(348

)

Ìý

Ìý

(278

)

Distributions paid to noncontrolling interests

Ìý

Ìý

(189

)

Ìý

Ìý

(162

)

Proceeds from the sale of noncontrolling interests

Ìý

Ìý

11

Ìý

Ìý

Ìý

5

Ìý

Purchases of noncontrolling interests

Ìý

Ìý

(41

)

Ìý

Ìý

(52

)

Repayments of advances from managed care payers

Ìý

Ìý

(11

)

Ìý

Ìý

�

Ìý

Other items, net

Ìý

Ìý

(39

)

Ìý

Ìý

(35

)

Net cash used in financing activities

Ìý

Ìý

(648

)

Ìý

Ìý

(2,661

)

Net increase (decrease) in cash and cash equivalents

Ìý

Ìý

(20

)

Ìý

Ìý

1,253

Ìý

Cash and cash equivalents at beginning of period

Ìý

Ìý

3,019

Ìý

Ìý

Ìý

1,228

Ìý

Cash and cash equivalents at end of period

Ìý

$

2,999

Ìý

Ìý

$

2,481

Ìý

Supplemental disclosures:

Ìý

Ìý

Ìý

Ìý

Interest paid, net of capitalized interest

Ìý

$

(99

)

Ìý

$

(162

)

Income tax payments, net

Ìý

$

(7

)

Ìý

$

(5

)

TENET HEALTHCARE CORPORATION

SEGMENT REPORTING

(Unaudited)

Ìý

Ìý

Ìý

Three Months Ended

Ìý

Ìý

March 31,

(Dollars in millions)

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Net operating revenues:

Ìý

Ìý

Ìý

Ìý

Ambulatory Care

Ìý

$

1,194

Ìý

Ìý

$

995

Ìý

Hospital Operations and Services

Ìý

Ìý

4,029

Ìý

Ìý

Ìý

4,373

Ìý

Total

Ìý

$

5,223

Ìý

Ìý

$

5,368

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Equity in earnings of unconsolidated affiliates:

Ìý

Ìý

Ìý

Ìý

Ambulatory Care

Ìý

$

54

Ìý

Ìý

$

56

Ìý

Hospital Operations and Services

Ìý

Ìý

2

Ìý

Ìý

Ìý

3

Ìý

Total

Ìý

$

56

Ìý

Ìý

$

59

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Adjusted EBITDA:

Ìý

Ìý

Ìý

Ìý

Ambulatory Care

Ìý

$

456

Ìý

Ìý

$

394

Ìý

Hospital Operations and Services

Ìý

Ìý

707

Ìý

Ìý

Ìý

630

Ìý

Total

Ìý

$

1,163

Ìý

Ìý

$

1,024

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Adjusted EBITDA margins:

Ìý

Ìý

Ìý

Ìý

Ambulatory Care

Ìý

Ìý

38.2

%

Ìý

Ìý

39.6

%

Hospital Operations and Services

Ìý

Ìý

17.5

%

Ìý

Ìý

14.4

%

Total

Ìý

Ìý

22.3

%

Ìý

Ìý

19.1

%

Ìý

Ìý

Ìý

Ìý

Ìý

Capital expenditures:

Ìý

Ìý

Ìý

Ìý

Ambulatory Care

Ìý

$

25

Ìý

Ìý

$

18

Ìý

Hospital Operations and Services

Ìý

Ìý

148

Ìý

Ìý

Ìý

222

Ìý

Total

Ìý

$

173

Ìý

Ìý

$

240

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #1 � Reconciliations of Net Income Available to Tenet Healthcare Corporation Common Shareholders to Adjusted Net Income Available to Common Shareholders

(Unaudited)

Ìý

Ìý

Ìý

Three Months Ended

Ìý

Ìý

March 31,

(Dollars in millions, except per share amounts)

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Net income available to Tenet Healthcare Corporation common shareholders

Ìý

$

406

Ìý

Ìý

$

2,151

Ìý

Less:

Ìý

Ìý

Ìý

Ìý

Impairment and restructuring charges, and acquisition-related costs

Ìý

Ìý

(19

)

Ìý

Ìý

(27

)

Litigation and investigation costs

Ìý

Ìý

(17

)

Ìý

Ìý

(4

)

Net gains on sales, consolidation and deconsolidation of facilities

Ìý

Ìý

22

Ìý

Ìý

Ìý

2,500

Ìý

Loss from early extinguishment of debt

Ìý

Ìý

�

Ìý

Ìý

Ìý

(8

)

Tax and noncontrolling interests impact of above items

Ìý

Ìý

6

Ìý

Ìý

Ìý

(634

)

Adjusted net income available to common shareholders

Ìý

$

414

Ìý

Ìý

$

324

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Diluted earnings per share

Ìý

$

4.27

Ìý

Ìý

$

21.38

Ìý

Less:

Ìý

Ìý

Ìý

Ìý

Impairment and restructuring charges, and acquisition-related costs

Ìý

Ìý

(0.20

)

Ìý

Ìý

(0.27

)

Litigation and investigation costs

Ìý

Ìý

(0.18

)

Ìý

Ìý

(0.04

)

Net gains on sales, consolidation and deconsolidation of facilities

Ìý

Ìý

0.23

Ìý

Ìý

Ìý

24.85

Ìý

Loss from early extinguishment of debt

Ìý

Ìý

�

Ìý

Ìý

Ìý

(0.08

)

Tax and noncontrolling interests impact of above items

Ìý

Ìý

0.06

Ìý

Ìý

Ìý

(6.30

)

Adjusted diluted earnings per share

Ìý

$

4.36

Ìý

Ìý

$

3.22

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Weighted average basic shares outstanding (in thousands)

Ìý

Ìý

94,242

Ìý

Ìý

Ìý

99,581

Ìý

Weighted average dilutive shares outstanding (in thousands)

Ìý

Ìý

95,019

Ìý

Ìý

Ìý

100,598

Ìý

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #2 � Reconciliations of Net Income Available to Tenet Healthcare Corporation Common Shareholders to Adjusted EBITDA

(Unaudited)

Ìý

Ìý

Ìý

Three Months Ended

Ìý

Ìý

March 31,

(Dollars in millions)

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Net income available to Tenet Healthcare Corporation common shareholders

Ìý

$

406

Ìý

Ìý

$

2,151

Ìý

Less:

Ìý

Ìý

Ìý

Ìý

Net income available to noncontrolling interests

Ìý

Ìý

(216

)

Ìý

Ìý

(183

)

Net income

Ìý

Ìý

622

Ìý

Ìý

Ìý

2,334

Ìý

Income tax expense

Ìý

Ìý

(143

)

Ìý

Ìý

(750

)

Loss from early extinguishment of debt

Ìý

Ìý

�

Ìý

Ìý

Ìý

(8

)

Other non-operating income, net

Ìý

Ìý

26

Ìý

Ìý

Ìý

25

Ìý

Interest expense

Ìý

Ìý

(204

)

Ìý

Ìý

(218

)

Operating income

Ìý

Ìý

943

Ìý

Ìý

Ìý

3,285

Ìý

Litigation and investigation costs

Ìý

Ìý

(17

)

Ìý

Ìý

(4

)

Net gains on sales, consolidation and deconsolidation of facilities

Ìý

Ìý

22

Ìý

Ìý

Ìý

2,500

Ìý

Impairment and restructuring charges, and acquisition-related costs

Ìý

Ìý

(19

)

Ìý

Ìý

(27

)

Depreciation and amortization

Ìý

Ìý

(206

)

Ìý

Ìý

(208

)

Adjusted EBITDA

Ìý

$

1,163

Ìý

Ìý

$

1,024

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Net operating revenues

Ìý

$

5,223

Ìý

Ìý

$

5,368

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues

Ìý

Ìý

7.8

%

Ìý

Ìý

40.1

%

Ìý

Ìý

Ìý

Ìý

Ìý

Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin)

Ìý

Ìý

22.3

%

Ìý

Ìý

19.1

%

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #3 � Reconciliations of Net Cash Provided by Operating Activities to

Free Cash Flow and Adjusted Free Cash Flow

(Unaudited)

Ìý

Ìý

Ìý

Three Months Ended

Ìý

Ìý

March 31,

(Dollars in millions)

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Net cash provided by operating activities

Ìý

$

815

Ìý

Ìý

$

586

Ìý

Purchases of property and equipment

Ìý

Ìý

(173

)

Ìý

Ìý

(240

)

Free cash flow

Ìý

$

642

Ìý

Ìý

$

346

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Net cash provided by (used in) investing activities

Ìý

$

(187

)

Ìý

$

3,328

Ìý

Net cash used in financing activities

Ìý

$

(648

)

Ìý

$

(2,661

)

Ìý

Ìý

Ìý

Ìý

Ìý

Net cash provided by operating activities

Ìý

$

815

Ìý

Ìý

$

586

Ìý

Less:

Ìý

Ìý

Ìý

Ìý

Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements

Ìý

Ìý

(36

)

Ìý

Ìý

(25

)

Adjusted net cash provided by operating activities

Ìý

Ìý

851

Ìý

Ìý

Ìý

611

Ìý

Purchases of property and equipment

Ìý

Ìý

(173

)

Ìý

Ìý

(240

)

Adjusted free cash flow

Ìý

$

678

Ìý

Ìý

$

371

Ìý

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #4 � Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted Net Income Available to Common Shareholders

(Unaudited)

Ìý

Ìý

Ìý

FY 2025

(Dollars in millions, except per share amounts)

Ìý

Low

Ìý

High

Net income available to Tenet Healthcare Corporation common shareholders

Ìý

$

1,057

Ìý

Ìý

$

1,202

Ìý

Less:

Ìý

Ìý

Ìý

Ìý

Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1)

Ìý

Ìý

(100

)

Ìý

Ìý

(50

)

Net gains on sales, consolidation and deconsolidation of facilities(2)

Ìý

Ìý

22

Ìý

Ìý

Ìý

22

Ìý

Tax and noncontrolling interests impact of above items

Ìý

Ìý

20

Ìý

Ìý

Ìý

10

Ìý

Adjusted net income available to common shareholders

Ìý

$

1,115

Ìý

Ìý

$

1,220

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Diluted earnings per share

Ìý

$

11.37

Ìý

Ìý

$

12.92

Ìý

Less:

Ìý

Ìý

Ìý

Ìý

Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements

Ìý

Ìý

(1.08

)

Ìý

Ìý

(0.55

)

Net gains on sales, consolidation and deconsolidation of facilities

Ìý

Ìý

0.24

Ìý

Ìý

Ìý

0.24

Ìý

Tax and noncontrolling interests impact of above items

Ìý

Ìý

0.22

Ìý

Ìý

Ìý

0.11

Ìý

Adjusted diluted earnings per share

Ìý

$

11.99

Ìý

Ìý

$

13.12

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Weighted average basic shares outstanding (in thousands)

Ìý

Ìý

92,000

Ìý

Ìý

Ìý

92,000

Ìý

Weighted average dilutive shares outstanding (in thousands)

Ìý

Ìý

93,000

Ìý

Ìý

Ìý

93,000

(1)

The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.

Ìý

(2)

The Company does not generally forecast net gains on sales, consolidation and deconsolidation of facilities or losses from the early extinguishment of debt because the Company does not believe that it can forecast these items with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to transactions that have already occurred in 2025.

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #5 � Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted EBITDA

(Unaudited)

Ìý

Ìý

Ìý

FY 2025

(Dollars in millions)

Ìý

Low

Ìý

High

Net income available to Tenet Healthcare Corporation common shareholders

Ìý

$

1,057

Ìý

Ìý

$

1,202

Ìý

Less:

Ìý

Ìý

Ìý

Ìý

Net income available to noncontrolling interests

Ìý

Ìý

(910

)

Ìý

Ìý

(960

)

Income tax expense

Ìý

Ìý

(425

)

Ìý

Ìý

(470

)

Interest expense

Ìý

Ìý

(805

)

Ìý

Ìý

(795

)

Other non-operating income, net

Ìý

Ìý

105

Ìý

Ìý

Ìý

115

Ìý

Net gains on sales, consolidation and deconsolidation of facilities(2)

Ìý

Ìý

22

Ìý

Ìý

Ìý

22

Ìý

Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1)

Ìý

Ìý

(100

)

Ìý

Ìý

(50

)

Depreciation and amortization

Ìý

Ìý

(805

)

Ìý

Ìý

(835

)

Adjusted EBITDA

Ìý

$

3,975

Ìý

Ìý

$

4,175

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Net income available to Tenet Healthcare Corporation common shareholders

Ìý

$

1,057

Ìý

Ìý

$

1,202

Ìý

Net operating revenues

Ìý

$

20,600

Ìý

Ìý

$

21,000

Ìý

Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues

Ìý

Ìý

5.1

%

Ìý

Ìý

5.7

%

Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin)

Ìý

Ìý

19.3

%

Ìý

Ìý

19.9

%

(1)

The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.

Ìý

(2)

The Company does not generally forecast net gains on sales, consolidation and deconsolidation of facilities or losses from the early extinguishment of debt because the Company does not believe that it can forecast these items with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to transactions that have already occurred in 2025.

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #6 � Reconciliations of Outlook Net Cash Provided by Operating Activities

to Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow

(Unaudited)

Ìý

Ìý

Ìý

FY 2025

(Dollars in millions)

Ìý

Low

Ìý

High

Net cash provided by operating activities

Ìý

$

2,500

Ìý

Ìý

$

2,850

Ìý

Purchases of property and equipment

Ìý

Ìý

(700

)

Ìý

Ìý

(800

)

Free cash flow

Ìý

$

1,800

Ìý

Ìý

$

2,050

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Net cash provided by operating activities

Ìý

$

2,500

Ìý

Ìý

$

2,850

Ìý

Less:

Ìý

Ìý

Ìý

Ìý

Payments for restructuring charges, acquisition-related costs and litigation costs and settlements(1)

Ìý

Ìý

(100

)

Ìý

Ìý

(50

)

Adjusted net cash provided by operating activities

Ìý

Ìý

2,600

Ìý

Ìý

Ìý

2,900

Ìý

Purchases of property and equipment

Ìý

Ìý

(700

)

Ìý

Ìý

(800

)

Adjusted free cash flow(2)

Ìý

$

1,900

Ìý

Ìý

$

2,100

(1)

The figures shown represent the Company's estimate for restructuring payments plus the actual year-to-date payments for restructuring charges, acquisition-related costs, and litigation costs or settlements. The Company does not generally forecast payments for acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.

Ìý

(2)

The Company’s definition of Adjusted Free Cash Flow does not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows From Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, and (ii) distributions paid to noncontrolling interests.

Ìý

Investor Contact

Will McDowell

469-893-2387

[email protected]

Media Contact

Robert Dyer

469-893-2640

[email protected]

Source: Tenet Healthcare Corporation

Tenet Healthcare Corp

NYSE:THC

THC Rankings

THC Latest News

THC Latest SEC Filings

THC Stock Data

15.14B
87.21M
0.9%
100.2%
3.5%
Medical Care Facilities
Services-general Medical & Surgical Hospitals, Nec
United States
DALLAS